Multiple Myeloma: all 3,712 studies
Page 33 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.TerminatedNCT00726869Phase 1
- A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple MyelomaCompletedNCT00725634Phase 1
- Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantTerminatedNCT00725062Phase 1
- Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00723359Phase 1
- Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple MyelomaCompletedNCT00722488Phase 1
- Natural Killer Cells and Bortezomib to Treat CancerCompletedNCT00720785Phase 1
- This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.No longer availableNCT00720603
- Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed MyelomaCompletedNCT00718601Phase 1
- Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell TransplantCompletedNCT00716911Not applicable
- Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesCompletedNCT00710528Phase 1
- A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.CompletedNCT00708292Phase 1/2
- A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With BortezomibWithdrawnNCT00706953Phase 2
- Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)Status unknownNCT00702247Phase 2
- Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant SurvivorsCompletedNCT00701844Not applicable
- European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast NephropathyCompletedNCT00700531Not applicable
- Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in MyelomaCompletedNCT00698776Phase 1
- Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell TransplantCompletedNCT00697684Phase 1
- Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedNCT00693433Phase 1
- A Phase 1 Safety Study of LY2127399 in Combination With BortezomibCompletedNCT00689507Phase 1
- Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)CompletedNCT00689000Phase 1/2
- Inflammatory Cytokines in Symptom Production in Multiple MyelomaCompletedNCT00688168
- Total Marrow Irradiation for Refractory Acute LeukemiaCompletedNCT00686556Phase 1
- Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantTerminatedNCT00674427Phase 1
- NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
- Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).CompletedNCT00665314Phase 2
- A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00664898Phase 1
- Efficacy Study of CYT997 in Multiple MyelomaTerminatedNCT00664378Phase 2
- Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple MyelomaCompletedNCT00657488Phase 2/3
- Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple MyelomaCompletedNCT00652041Phase 4
- T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantTerminatedNCT00651716
- Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple MyelomaTerminatedNCT00644306Phase 3
- Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)CompletedNCT00642395Phase 2
- The Molecular Characterization of Multiple Myeloma at RelapseCompletedNCT00639054
- High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell TransplantTerminatedNCT00637767Phase 2
- Nonmyeloablative Allo SCT for the Treatment of Hematologic DisordersCompletedNCT00636909Phase 2
- Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)CompletedNCT00633542Phase 3
- Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related DonorsCompletedNCT00618969Phase 2
- Everolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00618345Phase 2
- Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00616720Phase 2
- Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple MyelomaTerminatedNCT00609817Phase 1
- Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantCompletedNCT00602706Phase 1/2
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerCompletedNCT00602693Phase 1
- Thalidomide Versus Bortezomib in Melphalan Refractory MyelomaCompletedNCT00602511Phase 3
- Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose MelphalanTerminatedNCT00602147
- Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCTCompletedNCT00599495Phase 2
- Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)Status unknownNCT00598624Phase 2
- Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT00594126Phase 1
- A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple MyelomaCompletedNCT00592579Phase 2
- A Phase I Trial of ZIO-101 in Hematologic CancersCompletedNCT00592046Phase 1
- Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00590603Phase 1
- High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple MyelomaCompletedNCT00586014Phase 2
- Behavioral Intervention For BMT/SCT SurvivorsCompletedNCT00579917
- UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological MalignanciesWithdrawnNCT00578045Phase 1
- A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)WithdrawnNCT00577668Phase 2
- Therapeutic Research in Multiple MyelomaCompletedNCT00572338
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total TherapyActive, not recruitingNCT00572169Phase 3
- Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose ChemotherapyStatus unknownNCT00571168Phase 3
- Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple MyelomaCompletedNCT00570180Phase 2
- Investigation of the Cylex® ImmuKnow® AssayCompletedNCT00569842
- Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00568880Phase 1
- MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative ConditioningCompletedNCT00564200Phase 2
- Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer PatientsCompletedNCT00562224Phase 1
- A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma PatientsCompletedNCT00561743Phase 2
- Pethema Multiple Myeloma 2000CompletedNCT00560053Phase 3
- A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological MalignancyCompletedNCT00558675Phase 1/2
- Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple MyelomaCompletedNCT00555100Phase 1
- Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT00551928Phase 3
- Phase I Study for Safety and Efficacy of P276-00 in Subjects With MyelomaWithdrawnNCT00547404Phase 1
- Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 YearsStatus unknownNCT00546988Phase 3
- A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First RelapseCompletedNCT00546780Phase 3
- A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple MyelomaCompletedNCT00545519Phase 1
- Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic DisordersCompletedNCT00533923Phase 2
- Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.CompletedNCT00532675Phase 1
- Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple MyelomaCompletedNCT00532389Phase 1
- High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple MyelomaStatus unknownNCT00526734Phase 2
- Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT00525447Phase 1
- Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other DiseaseCompletedNCT00521430Not applicable
- A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple MyelomaWithdrawnNCT00516191Phase 1/2
- Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCTCompletedNCT00516152Phase 2
- Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic MalignanciesTerminatedNCT00514722Not applicable
- A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple MyelomaCompletedNCT00514371Phase 2/3
- Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic MalignanciesTerminatedNCT00513318
- Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic AnemiaCompletedNCT00513175
- Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaCompletedNCT00511082Phase 1
- Bortezomib and High-dose Melphalan at Myeloma RelapseStatus unknownNCT00508209Phase 2
- Etiology of Multiple Myeloma: A Case-Control StudyStatus unknownNCT00505999
- Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for MyelomaCompletedNCT00504634Phase 2
- Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple MyelomaWithdrawnNCT00504101Phase 1
- Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple MyelomaWithdrawnNCT00503763Phase 2
- Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With CancerWithdrawnNCT00499668Not applicable
- Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple MyelomaCompletedNCT00499577Phase 1/2
- A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)TerminatedNCT00499239Phase 1/2
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple MyelomaCompletedNCT00482846Phase 1
- Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With CancerStatus unknownNCT00482716Phase 3
- Bevacizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00482495Phase 2
- Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone PainCompletedNCT00482378Phase 1/2
- A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for MyelosuppressionCompletedNCT00482261Phase 2
- QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of ProgressionCompletedNCT00480363Phase 3
- Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00478075Phase 1/2